PhenytoinCAS# 57-41-0 |
- Metformin HCl
Catalog No.:BCC4799
CAS No.:1115-70-4
- Lenalidomide (CC-5013)
Catalog No.:BCC2245
CAS No.:191732-72-6
- Gliclazide
Catalog No.:BCC5002
CAS No.:21187-98-4
- Geniposide
Catalog No.:BCN5104
CAS No.:24512-63-8
- MEK inhibitor
Catalog No.:BCC1738
CAS No.:334951-92-7
- Imeglimin hydrochloride
Catalog No.:BCC4085
CAS No.:775351-61-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 57-41-0 | SDF | Download SDF |
| PubChem ID | 1775 | Appearance | Powder |
| Formula | C15H12N2O2 | M.Wt | 252.27 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | 5,5-Diphenylhydantoin | ||
| Solubility | DMSO : 100 mg/mL (396.40 mM; Need ultrasonic) | ||
| Chemical Name | 5,5-diphenylimidazolidine-2,4-dione | ||
| SMILES | C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3 | ||
| Standard InChIKey | CXOFVDLJLONNDW-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Phenytoin is an inactive voltage-gated sodium channel stabilizer.
Target: Sodium Channel
Phenytoin is an antiepileptic drug. It is useful to treat partial seizures and generalized tonic-clonic seizures but not primary generalized seizures such as absence seizures or myoclonic seizures. Phenytoin is believed to protect against seizures by causing voltage-dependent block of voltage-gated sodium channels [1]. Phenytoin has low affinity for resting sodium channels at hyperpolarized membrane potentials [2]. When neurons are depolarized and the channels transition into the open and inactivated states, greater binding and block occur. The inhibitory potency is strongly use dependent, so that block accumulates with prolonged or repetitive activation, such as occurs during a seizure discharge. The blocking of sodium channels by phenytoin is of slow onset. The time course of fast sodium currents is therefore not altered in the presence of the drug and action potentials evoked by synaptic depolarizations of ordinary duration are not blocked. Thus phenytoin is able to selectively inhibit pathological hyperexcitability in epilepsy without unduly impairing ongoing activity. Phenytoin also blocks persistent sodium current and this may be of particular importance in seizure control. Phenytoin is a class 1b antiarrhythmic [3]. References: | |||||
Phenytoin Dilution Calculator
Phenytoin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.964 mL | 19.82 mL | 39.6401 mL | 79.2801 mL | 99.1002 mL |
| 5 mM | 0.7928 mL | 3.964 mL | 7.928 mL | 15.856 mL | 19.82 mL |
| 10 mM | 0.3964 mL | 1.982 mL | 3.964 mL | 7.928 mL | 9.91 mL |
| 50 mM | 0.0793 mL | 0.3964 mL | 0.7928 mL | 1.5856 mL | 1.982 mL |
| 100 mM | 0.0396 mL | 0.1982 mL | 0.3964 mL | 0.7928 mL | 0.991 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Phenytoin is an inactive voltage-gated sodium channel stabilizer.
- Benactyzine hydrochloride
Catalog No.:BCC8841
CAS No.:57-37-4
- Pentobarbital sodium salt
Catalog No.:BCC6231
CAS No.:57-33-0
- Phenobarbital sodium salt
Catalog No.:BCC6230
CAS No.:57-30-7
- Strychnine
Catalog No.:BCN4978
CAS No.:57-24-9
- Vincristine
Catalog No.:BCN5411
CAS No.:57-22-7
- Urea
Catalog No.:BCC8034
CAS No.:57-13-6
- Stearic Acid
Catalog No.:BCN3820
CAS No.:57-11-4
- Palmitic acid
Catalog No.:BCN1206
CAS No.:57-10-3
- Flupirtine
Catalog No.:BCC4282
CAS No.:56995-20-1
- NSC 87877
Catalog No.:BCC2468
CAS No.:56990-57-9
- U 46619
Catalog No.:BCC7207
CAS No.:56985-40-1
- Boc-Cys(tBu)-OH
Catalog No.:BCC3379
CAS No.:56976-06-8
- Esromiotin
Catalog No.:BCC8325
CAS No.:57-47-6
- Fructose
Catalog No.:BCN4969
CAS No.:57-48-7
- Sucrose
Catalog No.:BCN5780
CAS No.:57-50-1
- Chlorotetracycline
Catalog No.:BCC8913
CAS No.:57-62-5
- Ethinyl Estradiol
Catalog No.:BCC3777
CAS No.:57-63-6
- Probenecid
Catalog No.:BCC4832
CAS No.:57-66-9
- Sulfaguanidine
Catalog No.:BCC4727
CAS No.:57-67-0
- Sulfamethazine
Catalog No.:BCC4942
CAS No.:57-68-1
- Progesterone
Catalog No.:BCN2198
CAS No.:57-83-0
- Testosterone propionate
Catalog No.:BCC9172
CAS No.:57-85-2
- Ergosterol
Catalog No.:BCN5787
CAS No.:57-87-4
- Cholesterol
Catalog No.:BCN2199
CAS No.:57-88-5
A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy.[Pubmed:28302415]
J Ayurveda Integr Med. 2017 Jan - Mar;8(1):37-41.
BACKGROUND: Genetic polymorphisms in drug metabolizing enzymes (DMEs) impart distinct drug metabolizing capacity and a unique phenotype to an individual. Phenytoin has large inter-individual variability in metabolism due to polymorphisms in CYP2C9 and CYP2C19. As per Ayurveda, Prakriti imparts a unique phenotype to an individual. OBJECTIVE: To assess whether Prakriti can substitute phenotyping [therapeutic drug monitoring (TDM)] and genotyping in individualizing therapy with Phenytoin in epilepsy patients. METHODS AND MATERIALS: This was a cross-sectional study conducted over a period of three years. Prakriti was assessed using standardized and validated software. Polymorphisms in CYP2C9 and CYP2C19 were assessed using Polymerase Chain Reaction (PCR)-Restriction fragment length polymorphism (PCR-RFLP). Plasma concentrations of Phenytoin (phenotype) were determined using reverse phase-high performance liquid chromatography (RF-HPLC). RESULTS: Total 351 patients were enrolled for the study. Kapha vata (KV) (39%) was the predominantly observed Prakriti followed by vata kapha (VK) (20.8%) and vata pitta (VP) (8.83%) among the patients. The CYP2C9 and CYP2C19 genotype distributions were in accordance with Hardy-Weinberg equilibrium. There was no association between Prakriti and genotypes and Prakriti and phenotype (p > 0.05 each). Patients with CYP2C9 *1/*3 genotype were thrice more likely to have toxic plasma concentrations of Phenytoin as compared to those with wild-type genotype (*1/*1) (Adjusted odds ratio - 3.36; 95% C.I. 1.61, 7.01). However, no such association was observed between polymorphisms of CYP2C19 and phenotype. CONCLUSIONS: We did not find any association between Prakriti and either phenotype or genotypes suggesting that Prakriti assessment would be of limited utility in individualizing Phenytoin therapy in epilepsy patients.
